Agalsidase beta biosimilar (JCR Pharmaceuticals)

阿加糖酶β生物类似药（JCR Pharmaceuticals）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAgalsidase beta biosimilar (JCR Pharmaceuticals)
Drug Alias Name阿加糖酶β生物仿制药（JCR Pharmaceuticals）agalsidasum beta (JCR Pharmaceuticals)Agalsidase beta (JCR Pharmaceuticals)Agalsidase beta biosimilar (JCR Pharmaceuticals/GlaxoSmithKline)Agalsidase β biosimilar - JCR Pharmaceuticals/GlaxoSmithKline +[7] 
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzymeBiologics > Biosimilar
Mechanisms of Actionglycosphingolipid hydrolysis activatorsglobotriaosylceramide (GL-3) hydrolysisα-Galactosidase replacements
TargetsGlycosphingolipid
Therapy Area/IndicationsFabry Disease
Global Approved IndicationsFabry Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2018/09/21
Country/TerritoryJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesJcr Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcJcr Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsFabry Disease
Inactive IndicationsN/A

Other Information

ATC CodeA16AB04
Related LinksN/A